A Pro504 --> Ser substitution in the beta-subunit of beta-hexosaminidase A inhibits alpha-subunit hydrolysis of GM2 ganglioside, resulting in chronic Sandhoff disease.
about
An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants)Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs diseaseCharacterization of the Glu and Asp residues in the active site of human beta-hexosaminidase BLysosomal sialidase (neuraminidase-1) is targeted to the cell surface in a multiprotein complex that facilitates elastic fiber assemblyIdentification of the 6-sulfate binding site unique to alpha-subunit-containing isozymes of human beta-hexosaminidasePyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones.Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on beta-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry.Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients.In cellulo examination of a beta-alpha hybrid construct of beta-hexosaminidase A subunits, reported to interact with the GM2 activator protein and hydrolyze GM2 gangliosideA single site in human beta-hexosaminidase A binds both 6-sulfate-groups on hexosamines and the sialic acid moiety of GM2 ganglioside.Characterization of beta-galactosidase mutations Asp332-->Asn and Arg148-->Ser, and a polymorphism, Ser532-->Gly, in a case of GM1 gangliosidosisCharacterization of the mutant β-subunit of β-hexosaminidase for dimer formation responsible for the adult form of Sandhoff disease with the motor neuron disease phenotype.Role of beta Arg211 in the active site of human beta-hexosaminidase B.
P2860
Q24601525-31374D05-3557-4BFF-A1DB-310308DC9B71Q24602248-DFAC63FD-4604-4DA1-BE69-EE4F91603F09Q24602842-D7D1189A-0639-483E-B966-3F674E885978Q28284064-C7A1AD31-9883-447B-A8FB-53A2FA6841DDQ28364049-01E6315E-015C-45C0-9C48-FD7E3FA76D33Q30829263-7DF6715E-F5FE-4E11-842F-C4F8FC2D24B2Q33275131-48BA1B89-32AC-4612-AB30-02231D6A8F0FQ33381275-334763AE-6204-4182-B458-881B1251EB18Q33998247-9AA99FE4-2703-41AB-98BE-6125CFB597FBQ34618426-971D7996-6D00-4B44-9252-AF45898A5A0BQ41945825-27C4FA82-51C4-48A2-9B1F-B3B21F904DB2Q42158395-4A05406D-C325-4475-BAF7-2924B256C569Q42425118-48835406-A691-4C23-9E50-1824C20BFC1AQ42702108-5CA7BABC-9432-4178-8541-270419CCA644
P2860
A Pro504 --> Ser substitution in the beta-subunit of beta-hexosaminidase A inhibits alpha-subunit hydrolysis of GM2 ganglioside, resulting in chronic Sandhoff disease.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
A Pro504 --> Ser substitution ...... g in chronic Sandhoff disease.
@en
type
label
A Pro504 --> Ser substitution ...... g in chronic Sandhoff disease.
@en
prefLabel
A Pro504 --> Ser substitution ...... g in chronic Sandhoff disease.
@en
P2093
P2860
P356
P1476
A Pro504 --> Ser substitution ...... g in chronic Sandhoff disease.
@en
P2093
P2860
P304
21386-21392
P356
10.1074/JBC.273.33.21386
P407
P577
1998-08-01T00:00:00Z